BrightSpring Health (BTSG) PT Raised to $64 at Stephens
Stephens analyst Dean Sublett raised the price target on BrightSpring Health (NASDAQ: BTSG) to $64.00 (from $53.00) while maintaining a Overweight rating.
The analyst commented: "BTSG's +7% revenue/+12% EBITDA beat was among the cleanest 1Q26 prints of our coverage, as the core Pharmacy business, led by Specialty & Infusion, grew per-script revenue and gross profit from strong therapy portfolio performance, favorable mix and contribution from the FFS business. More precisely, BTSG cited strong volumes across both brand LDDs and generics in addition to process improvements in Infusion (acute and chronic specialty both grew in the double digits). The -1.4% y/y decline in overall script volume primarily reflected previously discussed challenges to Home & Community script volumes as BTSG cycles through uneconomic customers rolling off and the bankruptcy of a large customer, a dynamic still expected to unwind around 3Q26. BTSG's raised 2026 outlook continues to assume sequential growth in revenue and EBITDA, albeit at more balanced levels compared to last year's performance. Raise estimates, TP to $64 (was $53). Reaffirm OW rating, Stephens Best Idea."